Key highlights
- Interim Phase 1 data showed a 27% best overall response rate in 22 evaluable SCCHN patients
- Confirmed objective response rate reached 29% for patients in the dose-escalation phase receiving at least 6 mg/kg
- Median duration of response was 10.2 months among responders in the dose-escalation portion
- Safety profile remains manageable with no reported cases of interstitial lung disease or ocular toxicity
- Management selected 7.5 mg/kg every three weeks as the recommended dose for further expansion studies
Phase 1 Clinical Outcomes
MacroGenics presented interim Phase 1 results for MGC026, its B7-H3-directed antibody-drug conjugate (ADC), at the 2026 European Society for Medical Oncology (ESMO) Congress. The trial evaluated the therapeutic candidate in patients with advanced solid tumors who had received a median of four prior lines of therapy. In the dose-escalation phase, 17 evaluable patients across 10 different tumor types demonstrated a confirmed objective response rate of 29% and a disease control rate of 65%. Pharmacokinetic data supported the selection of a 7.5 mg/kg dose for ongoing tumor-specific expansion, particularly in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Strategic Development Plans
- Initiation of a front-line metastatic SCCHN cohort evaluating MGC026 in combination with pembrolizumab
- Expansion of the current SCCHN monotherapy cohort to reach a target enrollment of 40 patients
- Continued monitoring of safety following reports of zero treatment-related discontinuations in the SCCHN cohort
- Evaluation of MGC026 potential as a differentiated B7-H3 targeting agent using proprietary drug-linker technology
Business and Pipeline Status
Headquartered in Rockville, Maryland, MacroGenics is refining its clinical focus following the recent $122.5 million sale of its GMP manufacturing operations to Bora Pharmaceuticals in July 2026. This divestiture, combined with regulatory milestones such as the $24.5 million payment following the U.S. approval of TZIELD, has bolstered the company's balance sheet. Management currently projects that its pro forma cash and marketable securities will fund operations through 2028. The pipeline remains active with other candidates, including the recent dosing of the first patient in a Phase 1 study of MGC030 for advanced solid tumors.
Financial and Market Context
MacroGenics currently maintains a market capitalization of approximately $143.3 million. Despite the clinical update presented at ESMO, the stock experienced a significant price decline of 38.02%, pushing the 14-day relative strength index (RSI) to 25.3, which technical analysts generally associate with oversold conditions. The company reported annual revenue of $149.5 million for the most recent fiscal year. Investors are looking forward to the release of third-quarter 2026 financial results, estimated for early November, and the presentation of Lorigerlimab Phase 2 data scheduled for later in the current ESMO Congress.
Down 3.6% since our story on 23 Oct: $2.25 when we broke it → $2.17 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $3.33 |
|---|---|
| 20 Oct | $3.49 |
| 21 Oct | $3.59 |
| 22 Oct | $3.63 |
| 23 Oct | $2.25 |
| 26 Oct | $2.19 |
| 27 Oct | $2.44 |
| 28 Oct | $2.47 |
| 29 Oct | $2.38 |
| 30 Oct | $2.40 |
| 2 Nov | $2.33 |
| 3 Nov | $2.33 |
| 4 Nov | $2.31 |
| 5 Nov | $2.22 |
| 6 Nov | $2.33 |
| 9 Nov | $2.34 |
| 10 Nov | $2.42 |
| 11 Nov | $2.32 |
| 12 Nov | $2.29 |
| 13 Nov | $2.20 |
| 16 Nov | $2.17 |
| Date | Announcement | Amount |
|---|---|---|
| 15 Oct 2026 | MacroGenics announced first patient dosed in Phase 1 study of MGC030 in advanced solid tumorsSource: ir.macrogenics.com | – |
| 11 Aug 2026 | MacroGenics announced achievement of milestone following Gilead's option exercise to license preclinical bispecific programSource: ir.macrogenics.com | $10.0 Million |
| 02 Jul 2026 | MacroGenics completed sale of GMP manufacturing operations to Bora PharmaceuticalsSource: ir.macrogenics.com | $122.5 Million |
| 22 Jun 2026 | MacroGenics announced regulatory milestone payment from Sanofi following U.S. approval of TZIELDSource: ir.macrogenics.com | $24.5 Million |
| 11 May 2026 | MacroGenics entered into agreement to sell GMP manufacturing operations to Bora PharmaceuticalsSource: ir.macrogenics.com | $122.5 Million |
Management commentary
“The emerging profile of MGC026 reinforces our conviction that this molecule has the potential to play an important and differentiated role in the treatment of advanced solid tumors.”
| Share price | $2.25 |
|---|---|
| Market cap | $143M |
| Revenue (annual) | $150M |
| 1-month price change | -40.79% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by MacroGenics, Inc. announcing interim Phase 1 clinical trial results for MGC026 presented at the ESMO 2026 Congress.
Track MACROGENICS INC live
Get the next MACROGENICS INC SEC filing seconds after it lands.